Immunogen and antibody composite vaccine and preparation method thereof

An immunogen and antibody technology, applied in the field of vaccines, can solve the problems of immune efficacy decline and disappearance

Inactive Publication Date: 2018-02-23
重庆更尚科技有限公司
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] 2. The immunogen and its antibody are a pair of contradictions. When the two meet, they will react to form antigen-antibody complexes, and their respective immune efficacy will decrease or even disappear.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunogen and antibody composite vaccine and preparation method thereof
  • Immunogen and antibody composite vaccine and preparation method thereof
  • Immunogen and antibody composite vaccine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0079] Example 1 Preparation of the composite vaccine of Riemeria anatipestifer immunogen and antibody

[0080] For the preparation process, see figure 1

[0081] 1) Preparation of the original immunophase: Add sterile Tween 80 at a final concentration of 3.5% (v / v) to the inactivated vaccine solution of Riemeria anatipestifer, and mix well to obtain the original immunology phase.

[0082] 2) Oil phase preparation: add Span 80 at a final concentration of 5% (v / v) to imported white oil, then add aluminum stearate at 3% of the total volume, autoclave for 20 minutes, and mix well That is, the oil phase is obtained.

[0083] 3) Preparation of the antibody phase: Add sterile Tween 80 with a final concentration of 0.9% (v / v) to the refined Riemeria anatipestifer egg yolk antibody solution, and mix well to form the antibody phase.

[0084] 4) Preparation of intermediates: the volume ratio of the immunogen phase to the antibody phase is 1:2. In a sterile environment, start the hom...

Embodiment 2

[0087] Example 2 Preparation of the composite vaccine of Riemeria anatipestifer immunogen and antibody

[0088] 1) Preparation of the original immunophase: Add sterile Tween 80 at a final concentration of 2% (v / v) to the inactivated vaccine solution of Riemeria anatipestifer, mix well to obtain the original immunology phase.

[0089] 2) Oil phase preparation: add Span 80 at a final concentration of 8% (v / v) to imported white oil, then add aluminum stearate at 2.5% w / v of the total volume, and autoclave for 20 minutes. After mixing, the oil phase is obtained.

[0090] 3) Preparation of antibody phase. Add sterile Tween 80 with a final concentration of 0.6% (v / v) to the refined Riemeria anatipestifer egg yolk antibody solution, and mix well to form the antibody phase.

[0091] 4) Preparation of intermediates: the volume ratio of the immunogen phase to the antibody phase is 1:2.3. Under a sterile environment, start the homogenizer, add the oil phase into the emulsification tan...

Embodiment 3

[0094] Example 3 Preparation of the composite vaccine of Riemeria anatipestifer immunogen and antibody

[0095] 1) Preparation of the original immunological phase: Add sterile Tween 80 at a final concentration of 4% (v / v) to the inactivated vaccine solution of Riemeria anatipestifer, and mix well to obtain the original immunological phase.

[0096] 2) Preparation of oil-free phase: use imported oil adjuvant and directly use it as oil phase.

[0097] 3) Preparation of antibody phase. Add sterile Tween 80 with a final concentration of 1.8% (v / v) to the refined Riemeria anatipestifer egg yolk antibody solution, and mix well to form the antibody phase.

[0098] 4) Preparation of intermediates: the volume ratio of the immunogen phase to the antibody phase is 1:3. In a sterile environment, start the homogenizer, add the oil phase into the emulsification tank, adjust the speed to 6500 rpm, and slowly add the original immune phase while stirring. After the addition of the immunogen p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an immunogen and antibody composite vaccine and a preparation method thereof. The composite vaccine consists of an immunogen at the center, an oil phase for coating the immunogen at the middle, and an antibody for coating the oil phase at the outer part, therefore, a water-in-oil-in-water (W/O/W) type emulsion system is formed. Within several hours after the composite vaccine is injected, the antibody is firstly and quickly released in the early stage, and then is absorbed by an organ and enters blood for immunization; the immunogen is then released, and is induced to generate effective active immunity within 4 to 6 days before the antibody loses the immunity. The composite vaccine has the advantage that seamless connection between specific passive immunity and specific active immunity is realized, adding complementation is achieved, and an effect can be taken quickly.

Description

technical field [0001] The invention belongs to the technical field of vaccines, in particular to a composite vaccine of an immunogen and an antibody and a preparation method thereof. Background technique [0002] Vaccines and antibodies belong to the category of biological products in drugs, and are specific drugs for the prevention and control of diseases caused by pathogens such as bacteria and viruses and diseases caused by biological toxins (such as snake venom). Edward Jenner in England invented the vaccinia vaccine to prevent smallpox in humans in 1798. 180 years later, that is, in 1979, the human application of the vaccine successfully eliminated smallpox, which was extremely harmful to it. In 1881, Louis Pasteur first discovered the immune efficacy of inactivated Pasteurella fowl cholera, and at the same time developed artificially weakened live vaccines for anthrax and rabies. After that, various vaccines came into being. In addition to the widely known vaccines...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/113A61K39/00A61K39/395A61P31/00
CPCA61K9/0019A61K9/113A61K39/00A61K39/395A61K2300/00
Inventor 黄伟黎容红洪晓萍
Owner 重庆更尚科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap